1
|
Gómez-Mesa JE, Gutiérrez-Posso JM, Escalante-Forero M, Eraso-Bolaños DE, Drazner MH, Quesada-Chaves D, Romero-Guerra A, Perna ER, Álvarez-Sangabriel A, Rossel V, Alarco W, Speranza M. American registry of ambulatory and acute decompensated heart failure (AMERICCAASS registry): Rationale and design. ESC Heart Fail 2024. [PMID: 39014556 DOI: 10.1002/ehf2.14965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 06/12/2024] [Accepted: 06/24/2024] [Indexed: 07/18/2024] Open
Abstract
AIMS Heart failure (HF) is a highly prevalent and progressive condition associated with significant morbidity and mortality rates. Acute decompensated HF precipitates millions of hospitalizations each year. Despite therapeutic advances, the overall prognosis of HF is poor. The varying clinical courses and outcomes of patients with this disease may be due to region-specific gaps and since most HF studies are conducted in developed countries, the participation of Latin American and Caribbean countries is low. Considering this, the American Registry of Ambulatory and Acute Decompensated Heart Failure (AMERICCAASS) aims to characterize the population with ambulatory and acute decompensated HF in the American continent and to determine rehospitalization and survival outcomes during the 12 months of follow-up. METHODS AND RESULTS AMERICCAASS Registry is an observational, prospective, and hospital-based registry recruiting patients with ambulatory or acute decompensated HF. The registry plans to include between two and four institutions per country from at least 20 countries in the Americas, and at least 60 patients recruited from each participant institution regardless of their ambulatory or acutely decompensated condition. Ambulatory patients with confirmed HF diagnosis or inpatients presenting with acute decompensated HF will be included. Follow-up will be performed at 12 months in ambulatory patients or 1, 6, and 12 months after hospital discharge in acutely decompensated HF patients. This ongoing study began on 1 April 2022, with recruitment scheduled to end on 30 November 2023, and follow-up on 31 January 2025. Ethics approval was obtained from the Biomedical Research Ethics Committee of Fundación Valle del Lili. Data collected in the AMERICCAASS registry is being stored on the electronic platform REDCap (Research Electronic Data Capture), which allows different forms for patient groups to enable unbiased analyses. For quantitative variables comparison, we will use the Student's t-test or non-parametric tests accordingly. Categorical variables will be presented as proportions, and groups will be compared with Fisher's exact test. The significance level will be <0.05 for comparisons. Readmissions and post-discharge mortality will be calculated as proportions at 1, 6, and 12 months, with a survival analysis by conditional probability and the Kaplan-Meier method. CONCLUSIONS AMERICCAASS Registry is intended to be the most important registry of the continent for obtaining important information about demographics, aetiology, co-morbidities, and treatment received, either ambulatory or hospitalized. This registry may contribute to the optimization of national and regional evidence and public policies for the diagnosis and treatment of HF disease.
Collapse
Affiliation(s)
- Juan Esteban Gómez-Mesa
- Department of Cardiology, Fundación Valle del Lili, Cali, Colombia
- Department of Investigation and Innovation, Fundación Valle del Lili, Cali, Colombia
- Department of Health Sciences, Universidad Icesi, Cali, Colombia
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
| | | | | | | | - Mark H Drazner
- Department of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Daniel Quesada-Chaves
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Cardiology, Hospital San Vicente de Paul, Heredia, Costa Rica
| | - Alexander Romero-Guerra
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Cardiology, Hospital Santo Tomas, Panama City, Panama
| | - Eduardo R Perna
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Heart Failure and Pulmonary Hypertension, Instituto De Cardiología J. F. Cabral, Corrientes, Argentina
| | - Amada Álvarez-Sangabriel
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Emergency Department and Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | - Víctor Rossel
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Cardiology, Instituto Nacional del Tórax, Santiago, Chile
- Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Walter Alarco
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Cardiology, Instituto Nacional Cardiovascular INCOR, Lima, Peru
| | - Mario Speranza
- Consejo Interamericano de Falla Cardíaca e Hipertensión Pulmonar (CIFACAH) de la Sociedad Interamericana de Cardiología (SIAC), Mexico City, Mexico
- Department of Cardiology, Hospital Clínica Bíblica, San José, Costa Rica
| |
Collapse
|
2
|
Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, Younis A, Dai H. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021; 28:1682-1690. [PMID: 33571994 DOI: 10.1093/eurjpc/zwaa147] [Citation(s) in RCA: 259] [Impact Index Per Article: 86.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 12/01/2020] [Accepted: 12/03/2020] [Indexed: 12/26/2022]
Abstract
AIMS To provide the first systematic analysis of the burden and underlying causes of heart failure (HF) in 195 countries and territories from 1990 to 2017. METHODS AND RESULTS We collected detailed information on prevalence, years lived with disability (YLDs), and underlying causes of HF from the Global Burden of Disease study 2017. Numbers and age-standardized rates of HF prevalence and YLDs were compared by age, sex, socio-demographic index (SDI), and location. The proportions of HF age-standardized prevalence rates due to 23 underlying causes were also presented. Globally, the age-standardized prevalence and YLD rates of HF in 2017 were 831.0 and 128.2 per 100 000 people, a decrease of -7.2% and -0.9% from 1990, respectively. Nevertheless, the absolute numbers of HF prevalent cases and YLDs have increased by 91.9% and 106.0% from 1990, respectively. There is significant geographic and socio-demographic variation in the levels and trends of HF burden from 1990 to 2017. Among all causes of HF, ischaemic heart disease accounted for the highest proportion (26.5%) of age-standardized prevalence rate of HF in 2017, followed by hypertensive heart disease (26.2%), chronic obstructive pulmonary disease (23.4%). CONCLUSION HF remains a serious public health problem worldwide, with increasing age-standardized prevalence and YLD rates in countries with relatively low SDI. More geo-specific strategies aimed at preventing underlying causes and improving medical care for HF are warranted to reduce the future burden of this condition.
Collapse
Affiliation(s)
- Nicola Luigi Bragazzi
- Department of General Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China.,Centre for Disease Modelling, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada.,Department of Health Sciences (DISSAL), Postgraduate School of Public Health, University of Genoa, Via Balbi 5, Genova 16126, Italy
| | - Wen Zhong
- Department of General Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China
| | - Jingxian Shu
- Department of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-sen University, 52 Mei Hua East Road, Zhuhai, Guangdong 519000, China
| | - Arsalan Abu Much
- Leviev Heart Center, Sheba Medical Center, Tel HaShomer, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Dor Lotan
- Leviev Heart Center, Sheba Medical Center, Tel HaShomer, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Avishay Grupper
- Leviev Heart Center, Sheba Medical Center, Tel HaShomer, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Arwa Younis
- Clinical Cardiovascular Research Center, University of Rochester Medical Center, 265 Crittenden Boulevard, Rochester, NY 14620, USA
| | - Haijiang Dai
- Centre for Disease Modelling, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
| |
Collapse
|